The Datex-Ohmeda S/5™ Oxygen Saturation Module, M-OSAT is intended for use with The Datex-Ohmeda modular multiparameter patient monitors for monitoring arterial oxygen saturation of hospitalized patients.

The Datex-Ohmeda S/5™ Oxygen Saturation Module, M-OSAT, and accessories are indicated for monitoring arterial oxygen saturation of hospitalized patients including monitoring during conditions of clinical patient motion. The device is indicated for use by qualified medical personnel only.

Device Description

The Datex-Ohmeda Oxygen Saturation Module, M-OSAT and accessories with TruTrak+ motion correction performance (later referred to as M-OSAT) is a module used to monitor arterial oxygen saturation. The user interface has been implemented in the main software of the following:

· AS/3 Anesthesia Monitor (K933285)
· AS/3 Compact Monitor (K933156) using S-STDxx or S-ARKxx software
· CS/3 Monitors (K974792) using S-ICUxx software
· AS/3 Anesthesia Monitor (K000815) using S-ANE99(A), L-ARK99(A)
· S/5 Compact Anesthesia Monitor (K002478) using S-00A05, S-00A06, L-00A07, L-00A08 software
· S/5 Compact Critical Care Monitor (K002158) using S-00C03, S-00C04 software.

M-OSAT is single-width plug-in parameter module including the arterial oxygen saturation and pulse rate measurements for a modular monitoring system. This module is designed with the following characteristics:

a single width plug-in module for the S/5 multiparameter monitor .
measuring noninvasive arterial oxygen saturation and pulse rate .
sensor consists of two light wavelengths LEDs and photodetector .
Datex-Ohmeda proprietary SpO2 measurement board Prologue .
an interface board for connecting the measurement board to the monitor .
uses TruTrak+ with motion performance correction technology for measuring . noninvasive arterial oxygen saturation during clinical motion

AI/ML Overview

This 510(k) summary does not contain a detailed study report with specific acceptance criteria and performance data in the format typically required for novel device submissions. Instead, it focuses on demonstrating substantial equivalence to a predicate device, primarily by highlighting that the new device (M-OSAT with TruTrak+ motion correction) maintains the same accuracy and measuring range with an additional specification for motion conditions.

However, based on the provided text, we can infer the acceptance criteria and reported performance related to the new feature in this submission (motion correction).

Here's an attempt to extract the information as requested, though it will be limited by the detail presented in the 510(k):

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria (from predicate device, extended for motion)	Reported Device Performance (M-OSAT with TruTrak+ motion)
Same accuracy and measuring range as predicate device.	Same accuracy and measuring range as predicate device.
Additional specification for 70% - 100% saturation range under clinical motion conditions.	70% - 100% +/- 3 digits under clinical motion conditions.

2. Sample Size Used for the Test Set and Data Provenance

The document does not specify the sample size for any clinical or non-clinical test sets.
The document does not specify the country of origin or whether the data was retrospective or prospective.

3. Number of Experts Used to Establish Ground Truth and Qualifications

The document does not provide any information regarding experts or ground truth establishment for a test set. The focus is on demonstrating compliance with standards and equivalence.

4. Adjudication Method for the Test Set

The document does not describe any adjudication method as it does not detail a study involving expert review for ground truth.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

The document does not mention or present a multi-reader multi-case (MRMC) comparative effectiveness study. The submission is for a device, not an AI-based interpretation tool for human readers.

6. Standalone Performance Study

The accuracy of the device (specifically the +/- 3 digits under motion conditions) is a measure of its standalone performance. However, the document does not provide details of a dedicated standalone study with methodology, exact sample sizes, or a comprehensive report. It states this as an "additional specification," implying testing was performed to establish this.

7. Type of Ground Truth Used

For oxygen saturation devices, the "ground truth" for accuracy is typically established through controlled desaturation studies where arterial blood gas samples are taken and analyzed by a co-oximeter or similar reference method. While the document doesn't explicitly state "co-oximetry," this is the industry standard for validating SpO2 accuracy. The document does not explicitly state the type of ground truth used but implies that the device's accuracy was verified.

8. Sample Size for the Training Set

This submission is for an oxygen saturation module, which typically relies on signal processing algorithms rather than machine learning models that require a "training set" in the conventional sense. Therefore, the concept of a training set sample size is not applicable in the context presented in this document. The "TruTrak+" technology likely refers to advanced signal processing for motion artifact reduction, which would be developed through engineering and signal processing techniques rather than a large labeled training dataset.

9. How the Ground Truth for the Training Set Was Established

As explained above, the concept of a training set and its ground truth in the machine learning sense is not applicable to this device as described. The "TruTrak+" likely refers to internal algorithmic development and testing against known motion artifacts and reference oxygen saturation values, rather than a labeled training dataset.

Summary

{0}------------------------------------------------

JUN 2 6 2001

Image /page/0/Picture/1 description: The image shows a black and white logo. The logo consists of a large black circle with a white letter "D" inside. There is a small black square in the upper right corner of the circle.

Premarket Notification 510(k) Summary As required by section 807.92 Datex-Ohmeda Oxygen Saturation Module, M-OSAT and accessorles (with TruTrak+ motion correction performance)

Page 1 of 4

11670

GENERAL COMPANY INFORMATION as required by 807.92(a)(1)

COMPANY NAME/ADDRESS/PHONE/FAX:

Datex-Ohmeda, Inc. 3 Highwood Drive Tewksbury, MA 01876 Tel: 978-640-0460 Fax: 978-640-0469

NAME OF CONTACT: Mr. Joel Kent FDA Official Correspondent

DATE:

May 26, 2001

DEVICE NAME as required by 807.92(a)(2)

TRADE NAME:

Datex-Ohmeda Oxygen Saturation Module, M-OSAT and accessories (with TruTrak+ motion correction performance)

COMMON NAME:

Oxygen Saturation Measurement Module, SPO2 Accessories

CLASSIFICATION NAME:

The following Class II classifications appear applicable:

Oximeter (per 21 CFR 870.2700) Ear Oximeter (per 21 CFR 870.2710)

Datex-Ohmeda, Inc. Three Highwood Drive Tewksbury, MA 01876 www.datex.ohmeda.com Telephone: 800-635-6099 978-640-0460 Facsimile: 978-640-0469

{1}------------------------------------------------

NAME OF LEGALLY MARKETED DEVICE FOR WHICH A CLAIM OF SUBSTANTIAL EQUIVALENCE IS MADE as required by 807.92(a)(3)

The Datex-Ohmeda Oxygen Saturation Module, M-OSAT and accessories (with TruTrak+ motion correction performance) is substantially equivalent in safety and effectiveness to the legally marketed (predicate) Datex-Ohmeda Oxygen Saturation Module, M-OSAT and accessories (K010463).

DEVICE DESCRIPTION as required by 807.92(a)(4)

· AS/3 Anesthesia Monitor (K933285)
· AS/3 Compact Monitor (K933156) using S-STDxx or S-ARKxx software
· CS/3 Monitors (K974792) using S-ICUxx software
· AS/3 Anesthesia Monitor (K000815) using S-ANE99(A), L-ARK99(A)
· S/5 Compact Anesthesia Monitor (K002478) using S-00A05, S-00A06, L-00A07, L-00A08 software
· S/5 Compact Critical Care Monitor (K002158) using S-00C03, S-00C04 software.

a single width plug-in module for the S/5 multiparameter monitor .
measuring noninvasive arterial oxygen saturation and pulse rate .
sensor consists of two light wavelengths LEDs and photodetector .
Datex-Ohmeda proprietary SpO2 measurement board Prologue .
an interface board for connecting the measurement board to the monitor .
uses TruTrak+ with motion performance correction technology for measuring . noninvasive arterial oxygen saturation during clinical motion

{2}------------------------------------------------

INTENDED USE as required by 807.92(a)(5)

The Datex-Ohmeda S/5™ Oxygen Saturation Module, M-OSAT, and accessories are I ne Dates Onlineda UP - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - monitoring during conditions of clinical patient motion. The device is indicated for use by qualified medical personnel only.

SUMMARY OF TECHNOLOGICAL CHARACTERITICS OF DEVICE COMPARED TO THE PREDICATE DEVICE as required by 807.92(a)(6)

The Datex-Ohmeda Oxygen Saturation Module, M-OSAT is substantially equivalent in safety and effectiveness to the legally marketed (predicate) M-OSAT Oxygen Saturation Module, (K010463).

The modified M-OSAT module has the following similarities and differences compared to the previously cleared M-OSAT (K010463) predicate device:

has the same indicated use, except with the addition of the phrase "including monitoring during conditions of clinical patient motion."
· uses the same operating principle, and the same electronic circuitry with the minor exception of a passive electrical component that was added to the Prologue board
· has the same safety and effectiveness
· has the same user interface and alarms, with the exception of the additional messages " <30", and ">250" for Pulse Rate range violations.
· has the same accuracy and measuring range, with the exception of the additional specification 70% - 100% +/-3 digits under clinical motion conditions
· uses the same accessories with the exception of three new OxyTip+ sensors that were added to replace previous devices
Interface board software was updated .
are manufactured using the same processes .

The modified Datex-Ohmeda Oxygen Saturation Module, M-OSAT, has the same intended use and indication for use as the previously cleared device, with the exception noted above.

The M-OSAT units are both intended for use with the Datex-Ohmeda modular multiparameter patient monitoring arterial oxygen saturation of hospitalized patients. Both are indicated for use by qualified medical personnel only.

The M-OSAT units both have the same user interface and alarm logic as the monitor, with the exception noted above. The data of both modules are receiving and showing on the monitor screen similar. Alarms of both modules have the same alarm menus and alarms can be adjusted equally.

{3}------------------------------------------------

The main differences between M-OSAT and the predicate are primarily due to fact that M-The maill differences betweed "TruTrak+" pulse oximetry technology to improve motion correction performance versus the predicate.

In summary, the Oxygen Saturation Module, M-OSAT, described in this submission is substantially equivalent to the predicate device

SUMMARY OF NONCLINICAL TESTING FOR THE DEVICE and CONCLUSIONS as required by 807.92(b)(1)(3)

The Datex-Ohmeda Oxygen Saturation Module, M-OSAT and accessories (with TruTrak+ The Datex-Onlineda Oxygen Salaranoly with the safety standards below and is therefore safe and effective for the intended use. The device has been thoroughly tested including sale and enced ve for the necessic compatibility, mechanical and environmental tolerance, electrical sarely, clouromagnetic compsiterions. Verification of compliance with the following mandatory and voluntary standards has been made:

IEC 60601-1: 1988 + Amdt 1:1991, Amdt 2:1995 .
EN 60601-1: 1990+ Amendments: A1: 1993, A2: 1995, A13: 1996 .
CAN/CSA C22.2 No. 601-1-M90 + S1 (1994)+Amdt2:1998 .
· UL 2601-1: 1997
· IEC 60601-1-2: 1993
FDA Reviewer Guidance for premarket notification submissions: 1993 .
IEC 60601-1-4: 1996 .
ANSI/AAMI ES1 (1993) .
IEC 601-2-26 (1994) .
ISO 9919: 1992
· EN 865:1997

Conclusion:

The summary above shows that there are no new questions of safety and effectiveness for Phe Sammeda Oxygen Saturation Module, M-OSAT and accessories (with TruTrak+ motion correction performance) as compared to the predicate device.

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird in flight. The symbol is composed of three curved lines that suggest wings and a body.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUN 2 6 2001

Mr. Joel Kent Datex Ohmeda, Inc. 3 Highwood Drive Tewksbury, MA 01876

Re: K011670

Datex-Ohmeda S/5TM Oxygen Saturation Module, M-OSAT, and accessories (with TruTrak+ Motion Correction Performance) Regulation Number: 870.2700 Regulatory Class: II (two) Product Code: 74 DQA Dated: May 27, 2001 Received: May 30, 2001

Dear Mr. Kent:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this

{5}------------------------------------------------

Page 2 - Mr. Joel Kent

response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours.

Don K. Tellh

James E. Dillard III Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

KOII670 510(k) Number (if known): _

Device Name: Datex-Ohmeda S/5™ Oxygen Saturation Module, M-OSAT, and accessories (with TruTrak+ Motion Correction Performance)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use	✓
(Per 21 CFR 801.109)

Over-The-Counter Use
(Optional Format 1-2-96)

Division of Cardiovascular & Respiratory Devices510(k) Number

Regulation Number and Section

§ 870.2700 Oximeter.

(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).